GLA and Fabry disease: While treatment with agalsidase alfa for ≥10 years has been shown to promote clinical stability in patients with FD who had normal kidney function at treatment initiation, when compared with untreated patients with FD [19], our analyses suggest that long-term treatment with agalsidase alfa may be beneficial to patients with known GLA gene pathogenic variants, regardless of their clinical characteristics at treatment start.